DBV Technologies (NASDAQ:DBVT) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of DBV Technologies (NASDAQ:DBVT) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other analysts also recently commented on DBVT. Citizens Jmp boosted their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price objective on shares of DBV Technologies in a research note on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research report on Thursday, December 18th. Finally, Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $38.65.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $20.00 on Friday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -3.83 and a beta of -0.97. The stock has a 50-day simple moving average of $21.58 and a 200-day simple moving average of $17.28. DBV Technologies has a 52-week low of $5.30 and a 52-week high of $26.18.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, March 26th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). The firm had revenue of $0.64 million during the quarter, compared to analyst estimates of $1.06 million. DBV Technologies had a negative return on equity of 310.56% and a negative net margin of 2,606.83%. As a group, equities research analysts predict that DBV Technologies will post -7.05 earnings per share for the current year.

Institutional Trading of DBV Technologies

Several large investors have recently modified their holdings of the company. Artisan Partners Limited Partnership raised its holdings in DBV Technologies by 6,273.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after acquiring an additional 3,257,135 shares during the period. Siren L.L.C. bought a new stake in DBV Technologies during the fourth quarter valued at about $35,606,000. Vivo Capital LLC grew its position in shares of DBV Technologies by 133.4% in the fourth quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock valued at $47,189,000 after purchasing an additional 1,407,120 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of DBV Technologies in the second quarter valued at about $9,659,000. Finally, MPM Bioimpact LLC bought a new position in shares of DBV Technologies in the second quarter worth about $9,649,000. 71.74% of the stock is owned by institutional investors.

Key DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.